title: A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension.
abstract: Several reports have demonstrated that the efficacy of latanoprost is influenced by the time of dosing. This model-based meta-analysis validates previous findings that evening dosing is superior to morning dosing and predicts the optimal time for dosing, based on the quantitative assessment of baseline and latanoprost-treated 24-h circadian intraocular pressure (IOP) curves. The results confirm the importance of the time of dosing as a factor that influences the extent of reduction in IOP and underline the need to take this factor into consideration in the design of glaucoma trials and therapy.
authors.affiliation: Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, La Jolla, California, USA. kenneth.luu@pfizer.com
authors.forename: K T
authors.initials: KT
authors.lastname: Luu
authors.forename: S R
authors.initials: SR
authors.lastname: Raber
authors.forename: D J
authors.initials: DJ
authors.lastname: Nickens
authors.forename: P
authors.initials: P
authors.lastname: Vicini
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002940:Circadian Rhythm; D004334:Drug Administration Schedule; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost